Mihaly Hajos, PharmD, PhD
DownloadHi-Res Photo
Cards
Appointments
Comparative Medicine
Primary
Contact Info
About
Titles
Professor Adjunct
Biography
Mihaly Hajos is a Professor Adjunct at the Section of Comparative Medicine, leading the Laboratory of Translational Neuropharmacology. He received a Pharm.D. degree from Albert Szent-Gyorgyi Medical University, Szeged, Hungary, and a Ph.D. from University of Goteborg, Sweden. His research interest includes neurobiology and pharmacology of psychiatric and neurological disorders, application of systems electrophysiology in drug discovery, and translational aspects of neurophysiological measures from preclinical to clinical studies.
Appointments
Comparative Medicine
Professor AdjunctPrimary
Other Departments & Organizations
Education & Training
- PhD
- University of Goteborg, Pharmacology, Medical School
- PharmD
- A. Szent-Gyorgyi Medical University, Physiology and Pathophysiology
Research
Overview
Medical Subject Headings (MeSH)
Mental Disorders
Research at a Glance
Publications Timeline
A big-picture view of Mihaly Hajos's research output by year.
11Publications
83Citations
Publications
2024
Cognito’s non-invasive medical device demonstrates durable effects on activities of daily living through OVERTURE open-label extension study. (N2.002)
Kern R, Kuang C, Hajos M, Konisky A, Boasso A, Hempel E, Vaughan B, Seshagiri C, Malchano Z, Hendrix S, Saikali K, Massey J, Arjunji R. Cognito’s non-invasive medical device demonstrates durable effects on activities of daily living through OVERTURE open-label extension study. (N2.002). Neurology 2024, 102 DOI: 10.1212/wnl.0000000000205670.Peer-Reviewed Original ResearchSafety, tolerability, and efficacy estimate of evoked gamma oscillation in mild to moderate Alzheimer’s disease
Hajós M, Boasso A, Hempel E, Shpokayte M, Konisky A, Seshagiri C, Fomenko V, Kwan K, Nicodemus-Johnson J, Hendrix S, Vaughan B, Kern R, Megerian J, Malchano Z. Safety, tolerability, and efficacy estimate of evoked gamma oscillation in mild to moderate Alzheimer’s disease. Frontiers In Neurology 2024, 15: 1343588. PMID: 38515445, PMCID: PMC10957179, DOI: 10.3389/fneur.2024.1343588.Peer-Reviewed Original ResearchAltmetricConceptsAssessment of adverse eventsMild to moderate ADGamma oscillationsModerate ADAmyloid-related imaging abnormalitiesAlzheimer's diseaseMild-to-moderate Alzheimer's diseaseSecondary clinical outcome measuresTherapy systemPrimary outcome measureHigher adherence ratesWhole-brain volumeClinical outcome measuresSecondary outcome measuresModerate Alzheimer's diseaseDisease-modifying effectsBaseline MMSE scoreStudy discontinuationExperimental AD modelsWell-toleratedEfficacy outcomesClinical benefitAdverse eventsDaily treatmentClinical criteriaNoninvasive Gamma Sensory Stimulation May Reduce White Matter and Myelin Loss in Alzheimer’s Disease
Da X, Hempel E, Ou Y, Rowe O, Malchano Z, Hajós M, Kern R, Megerian J, Cimenser A. Noninvasive Gamma Sensory Stimulation May Reduce White Matter and Myelin Loss in Alzheimer’s Disease. Journal Of Alzheimer's Disease 2024, 97: 359-372. PMID: 38073386, PMCID: PMC10789351, DOI: 10.3233/jad-230506.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsWhite matter atrophyActive treatment participantsMatter atrophyAlzheimer's diseaseMyelin lossTreatment participantsWhite matterNeuronal network functionT2-weighted MRIEarly disease interventionMRI outcomesClinical trialsEntorhinal regionWhite matter structuresHz stimulationMagnetic resonance imaging dataAfferent connectionsInclusion criteriaTherapeutic approachesAtrophySensory stimulationVolume assessmentDisease interventionDiseaseMyelin content
2023
Lobe‐specific changes in white matter volume and myelination following 6‐month 40 Hz gamma sensory stimulation in patients on the Alzheimer’s disease spectrum
Cimenser A, Da X, Hempel E, Malchano Z, Vaughan B, Megerian J, Hajos M. Lobe‐specific changes in white matter volume and myelination following 6‐month 40 Hz gamma sensory stimulation in patients on the Alzheimer’s disease spectrum. Alzheimer's & Dementia 2023, 19 DOI: 10.1002/alz.073143.Peer-Reviewed Original ResearchConceptsWhite matter volumeAlzheimer's diseaseWhite matterPlacebo groupTemporal lobeMatter volumeFrontal lobeParietal lobeWhite matter atrophyGray matter changesMRI T1 imagesTreatment group resultsMonth 3Month 6Neurological comorbiditiesT1w/T2w ratioMatter atrophyAD patientsMagnetic resonance imaging dataPathological changesOccipital lobePlacebo participantsMatter changesNeuronal activityTreatment groupsSensory‐Evoked 40Hz Gamma Oscillation: A Feasible and Promising Treatment Option for Alzheimer’s Disease
Hajos M, Boasso A, Cimenser A, Shpokayte M, Hempel E, Da X, Seshagiri C, Megerian J, Vaughan B, Malchano Z. Sensory‐Evoked 40Hz Gamma Oscillation: A Feasible and Promising Treatment Option for Alzheimer’s Disease. Alzheimer's & Dementia 2023, 19 DOI: 10.1002/alz.072957.Peer-Reviewed Original ResearchConceptsClinical trialsAlzheimer's diseaseActive armPotential novel therapeutic interventionsSensory stimulationOccipital cortical thicknessAmyloid plaque loadAbnormal neuronal activityPivotal clinical trialsStimulation systemPromising treatment optionDifferent therapeutic approachesNovel therapeutic interventionsMinimal side effectsQuantitative MRI analysisNeuronal network oscillationsDaily therapyPlaque loadADCS-ADLBrain atrophyClinical presentationTreatment armsClinical benefitClinical efficacyAD pathologyDecay in Entorhinal White Matter/Gray Matter contrast in Alzheimer’s Disease Patients is reduced by 40Hz sensory stimulation
Da X, Hempel E, Malchano Z, Vaughan B, Megerian J, Hajos M, Cimenser A. Decay in Entorhinal White Matter/Gray Matter contrast in Alzheimer’s Disease Patients is reduced by 40Hz sensory stimulation. Alzheimer's & Dementia 2023, 19 DOI: 10.1002/alz.077337.Peer-Reviewed Original ResearchConceptsMagnetic resonance imagingEntorhinal regionAlzheimer's diseaseWhite matterPlacebo groupDisease patientsMRI measuresTreatment groupsPlacebo-controlled feasibility studyPhase I/IISensory stimulationMonth 6 visitMonths of treatmentStructural magnetic resonance imagingAlzheimer's disease patientsSignal intensityT1 magnetic resonance imagingLinear mixed-effects modelingMonth 3WM atrophyMyelin lossAD severityWM/GM contrastMixed-effects modelingAD patientsA Randomized, Double‐blind, Sham‐controlled, Adaptive‐Design Pivotal Trial of Sensory Stimulation in Subjects with Alzheimer’s Disease
Boasso A, Houser C, Hajos M, Newberger J, Seshagiri C, Leach J, Konisky A, Galley A, Hempel E, Dickson S, Hendrix S, Malchano Z, Megerian J. A Randomized, Double‐blind, Sham‐controlled, Adaptive‐Design Pivotal Trial of Sensory Stimulation in Subjects with Alzheimer’s Disease. Alzheimer's & Dementia 2023, 19 DOI: 10.1002/alz.080670.Peer-Reviewed Original ResearchConceptsMini-Mental State ExamClinical Dementia Rating ScaleZarit Burden IndexPivotal trialsSensory stimulationAlzheimer's Disease Cooperative Study-ActivitiesConcurrent medication useOccipital cortical thicknessKey secondary outcomesProspective clinical trialsPrimary outcome measureSelf-administered therapyClinical laboratory assessmentsClinical efficacy assessmentBrain structural changesDaily living testDementia Rating ScaleSubgroup of subjectsMental State ExamAlzheimer's disease symptomsHOPE trialSecondary outcomesAdverse eventsMedication useADCS-ADLEPH230 Estimating Risk of Disease Progression from Mild Cognitive Impairment (MCI) to Alzheimer’s Disease (AD) Using Administrative Claims
Gregory S, Abdelhadi J, Conroy B, Yoon L, Irwin D, Malchano Z, Hajos M, Megerian J, Grundman M, Crosland E. EPH230 Estimating Risk of Disease Progression from Mild Cognitive Impairment (MCI) to Alzheimer’s Disease (AD) Using Administrative Claims. Value In Health 2023, 26: s204-s205. DOI: 10.1016/j.jval.2023.03.2576.Peer-Reviewed Original Research
2022
Coherent Activity in EEG Response to Gamma Sensory Stimulation Predicts Positive Outcome in Cognitive and Functional Abilities, and Brain Atrophy in Subjects with Alzheimer’s Disease (P4-6.004)
Cimenser A, Mrozak H, Da X, Travers T, Hempel E, Seshagiri C, Boasso A, Vaughan B, Megerian J, Malchano Z, Hajos M. Coherent Activity in EEG Response to Gamma Sensory Stimulation Predicts Positive Outcome in Cognitive and Functional Abilities, and Brain Atrophy in Subjects with Alzheimer’s Disease (P4-6.004). Neurology 2022, 98 DOI: 10.1212/wnl.98.18_supplement.1799.Peer-Reviewed Original ResearchFeasibility, Safety, and Efficacy of Gamma Sensory Stimulation as a Novel Therapeutic Intervention for Alzheimer’s Disease (N1.001)
Megerian J, Hajos M, Hempel E, Cimenser A, Boasso A, Cotter C, Williams M, Kwan K, Nicodemus-Johnson J, Hendrix S, Vaughan B, Malchano Z. Feasibility, Safety, and Efficacy of Gamma Sensory Stimulation as a Novel Therapeutic Intervention for Alzheimer’s Disease (N1.001). Neurology 2022, 98 DOI: 10.1212/wnl.98.18_supplement.1936.Peer-Reviewed Original ResearchCitations